D. Rekić

发表

Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access.

I. Zineh, Shiew-Mei Huang, Lei Zhang, 2017, Journal of pharmaceutical sciences.

Quantitative Clinical Pharmacological Studies on Efavirenz and Atazanavir in the Treatment of HIV-1 Infection

D. Rekić, 2012 .

Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance

H. Tomkinson, A. Berges, J. Parkinson, 2021, British journal of clinical pharmacology.

A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients

Jianmeng Chen, Yaning Wang, B. Chowdhury, 2020, Journal of pharmacokinetics and pharmacodynamics.

Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data

B. Scirica, J. Nyström, I. Raz, 2022, PloS one.

An oral antisense oligonucleotide for PCSK9 inhibition

P. Gennemark, B. Monia, M. Hölttä, 2021, Science Translational Medicine.

Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy

A. Sönnerborg, M. Gisslén, M. Ashton, 2011, The AAPS Journal.

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

C. Nilsson, I. Azarov, C. Dota, 2022, British journal of clinical pharmacology.

Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine.

L. Barregard, M. Horvat, T. Lundh, 2011, Toxicological sciences : an official journal of the Society of Toxicology.

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

Daniel Röshammar, M. Ashton, Michael Ashton, 2011, British journal of clinical pharmacology.

HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects

L. Gustafsson, M. Ashton, P. Waako, 2011, Clinical pharmacokinetics.

New Advancements in Exposure-Response Analysis to Inform Regulatory Decision Making

V. Sinha, Liang Zhao, N. Mehrotra, 2016 .

In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.

Shiew-Mei Huang, Lei Zhang, A. Galetin, 2017, Journal of pharmaceutical sciences.

A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases

J. Leander, Mikael Sunnåker, U. Eriksson, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis

Yaning Wang, B. Chowdhury, Y. Bi, 2017, Annals of the American Thoracic Society.

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus

D. Boulton, Weifeng Tang, B. Hamrén, 2021, Journal of clinical pharmacology.

Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight

J. Leander, D. Rekić, S. Johansson, 2020, Clinical Pharmacokinetics.

Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

G. Schiavon, V. Voronova, J. Parkinson, 2021, British journal of clinical pharmacology.

QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019

H. Tomkinson, A. Berges, J. Parkinson, 2021, Journal of clinical pharmacology.

A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients

Jianmeng Chen, Yaning Wang, B. Chowdhury, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients

M. Gisslén, A. Calcagno, J. Tarning, 2012, The AAPS Journal.

Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease

M. Åstrand, M. Någård, B. Hamrén, 2021, Clinical Pharmacokinetics.

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study

L. Ottesen, J. Strauss, T. Wise-Draper, 2023, Cancer Chemotherapy and Pharmacology.

Verinurad does not prolong QTc interval: a thorough QT study using concentration–QTc modelling

C. Gottfridsson, J. Parkinson, C. Dota, 2022, British Journal of Clinical Pharmacology.

Model based design and analysis of phase II HIV-1 trials

U. Simonsson, D. Röshammar, D. Rekić, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II

P. Gennemark, B. Hamrén, C. Nilsson, 2022, CPT: pharmacometrics & systems pharmacology.

Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine.

L. Barregard, M. Horvat, T. Lundh, 2011, Toxicological sciences : an official journal of the Society of Toxicology.